Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?

The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers a lower-cost entry into diversified pharmaceutical leaders, while the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) targets high-growth biotech and genetic engineering firms.

Both funds target the healthcare sector but with distinct strategic focuses. The healthcare sector often presents a choice between the high-growth potential of biotech and the established revenue streams of major pharmaceuticals. While both funds provide targeted exposure, they differ in portfolio construction and historical volatility profiles. Investors must decide between specialized innovation and larger pharmaceutical giants.

Snapshot (cost & size)

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

The iShares U.S. Pharmaceuticals ETF is the more affordable option with a 0.37% expense ratio, saving investors 0.21 percentage points annually over the Invesco Biotechnology & Genome ETF. While the Invesco fund offers a slightly higher 1.6% dividend yield, the iShares fund provides a competitive 1.4% payout. Expense ratios represent the annual fee taken from fund assets, and lower fees are generally preferred by long-term investors.

Performance & risk comparison

What's inside

The iShares U.S. Pharmaceuticals ETF holds 56 positions and focuses exclusively on the healthcare sector. Its largest positions include Johnson & Johnson (NYSE:JNJ) at 22.19%, Eli Lilly (NYSE:LLY) at 21.78%, and Bristol Myers Squibb (NYSE:BMY) at 4.65%. The fund was launched in 2006. It tracks a market-cap-weighted index of U.S. pharmaceutical companies, leading to significant concentration in its top two holdings. iShares U.S. Pharmaceuticals ETF has paid $1.47 per share over the trailing 12 months, which, at its recent ~$102.99 share price, works out to a 1.4% yield.

The Invesco Biotechnology & Genome ETF maintains a smaller portfolio of 31 healthcare stocks. Its top holdings include Regeneron Pharmaceuticals (NASDAQ:REGN) at 5.44%, Amgen (NASDAQ:AMGN) at 5.36%, and Vertex Pharmaceuticals (NASDAQ:VRTX) at 5.23%. The fund was launched in 2005. It employs a quantitative methodology that evaluates U.S. companies based on price momentum, earnings growth, and management decisions. Invesco Biotechnology & Genome ETF has paid $1.55 per share over the trailing 12 months, which, on its recent ~$94.22 share price, works out to a 1.6% yield.

For more guidance on ETF investing, check out the full guide at this link.

Which looks like the better buy

IHE's five-year run has been the smoother and, in that window, the more rewarding one: less volatility, a shallower drawdown, and a better total return than PBE. Zoom out closer to a decade, though, and biotech comes out ahead, so this isn't a simple growth-versus-stability story. It's really about which window you're measuring, and which one you'll actually hold through. That comes down to time horizon and risk tolerance. IHE's returns lean heavily on Johnson & Johnson and Eli Lilly, which together account for nearly half of the portfolio. That's a concentrated bet on two large drugmakers rather than a diversified basket, but it's held up well recently. PBE spreads bets across more, smaller names using a momentum-based approach, which means more exposure to catalysts like trial readouts and FDA decisions, and stretches where it trails pharma before it doesn't. IHE is the easier core holding: cheaper, steadier, and proven over a full cycle. PBE fits as a satellite position for investors who can sit through drawdowns like 2021's in pursuit of longer-term upside. As with many investing strategies, your own mindset is a major factor to weigh.

Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.